Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VaxThera Zika vaccine
- Development stage
- Preclinical
- Lead developer
- VaxThera
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
01
Overview
VaxThera's Zika vaccine is a preclinical candidate being developed using both viral vector and mRNA platforms. The project is a collaborative effort between VaxThera, the University of Wisconsin, and the Universidad Nacional de Colombia, with co-funding from the Colombian Ministry of Science, Technology, and Innovation (Ministerio de Ciencia, Tecnología e Innovación de Colombia). The vaccine aims to induce protective immunity against the Zika virus by leveraging genetic delivery technologies to express viral antigens and stimulate neutralizing antibody and T-cell responses.
- Other names
- Zika vaccine (VaxThera)
Beyond the preview
Go deeper on VaxThera Zika vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VaxThera Zika vaccine.